Please assess the completion status of the following clinical trial:

Trial Title: Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with cystic fibrosis related diabetes aged over 10 years (no upper age limite)~* Patient treated by multiple insulin injections (minimal three insulin injections per day or basal bolus insulin regimen) or insulin pump~* Patient with CGM from over 3 months (at the signature of the study's informed consent) or patient not wearing a CGM device, but agreeing a CGM at the inclusion and at the end of each treatment period of 3 months~* Naive patient of Fiasp or patient under Fiasp, having carried out a run-in period of one month with rapid acting insulin treatment~* Affiliated to a social security scheme~* Subject able to understand the objectives and the risks related to the research and to give a dated and signed informed consent~* Subject having been informed of the results of the prior medical examination~* Written informed consent, dated and signed before initiating any trial-related procedure (if the subject is a minor, the consent must be signed by the 2 legal representative and the patient if he/she is able to give consent)~Exclusion Criteria:~* Patient with type 1 or type 2 diabetes~* Patient with cystic fibrosis related diabetes treated with 2 injections / day~* Patient with an HbA1C greater than 12% who demonstrate therapeutic non-compliance~* Patient pregnant (positive urinary pregnancy test) or wishing to pregnancy~* Contraindication to Aspart insulin~* Patient on lung transplant waiting list or transplanted within one year prior to the inclusion visit~* Patient who started treatment with Trikafta® within 3 months prior to the inclusion visit~* Patient who cannot be followed during 12 months~* Subject in exclusion period (determined by previous or current clinical study)~* Impossibility of giving the subject enlightened information (subject in emergency situation, difficulties of understanding, cognitive impairment...)~* Subject under the protection of justice~* Subject under guardianship or curatorship

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: A-F-A-F (Type: ACTIVE_COMPARATOR): The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study.~All patients will test both insulin treatments (A and F) in alternating periods.~The patients of group 1 will start with pre-prandial aspart insulin (NovoRapid).~Each treatment period will last 3 months.
- Groupe 2: F-A-F-A (Type: ACTIVE_COMPARATOR): The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study.~All patients will test both insulin treatments (A and F) in alternating periods.~The patients of group 2 will start with post prandial Faster-acting aspart insulin (FIASP).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues